- Poster presentation
- Open Access
PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
Pediatric Rheumatology volume 11, Article number: P169 (2013)
Interleukin-1β (IL-1β) plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Efficacy and safety of canakinumab (CAN), a selective, fully human, anti- IL-1β monoclonal antibody, have been demonstrated in 2 phase III trials. Here we present 12-week results of a post-hoc pooled analysis.
To evaluate the 12-week efficacy of CAN 4 mg/kg in treatment naïve patients (pts).
Data from the 3 trials done as part of the phase III program were pooled for this analysis. Pts aged 2-19 yrs with active SJIA were enrolled and received subcutaneous CAN 4 mg/kg or placebo. The post-hoc analysis presented here focuses on SJIA response to CAN therapy in the initial treatment period of a total of 178 CAN-naïve pts. Methodological factors precluded a comparator group, so this analysis is of a descriptive nature.
At baseline (BL), 94% of pts had intermittent spiking fever due to SJIA; and 73% were on steroids (mean dose of 0.38 mg/kg/d). In the pooled analysis (N = 178), by Week 2 evidence of profound clinical benefit was observed (Table 1) with 20% of pts even achieving inactive disease.
The median CRP level of 158 mg/L at BL decreased by a median of 82% and 94% by weeks 2 and 12, respectively. Rapid improvements were also observed in the number of active joints. The median number of active joints decreased from 10 at BL to 2.5 at Week 2 and 0 at Week 12. Similarly, for joints with limitation of motion, median values decreased from 9 at BL to 2.5 and 1 at Week 2 and 12, respectively. While 94% pts had fever due to SJIA at BL, only 13% at Week 2 and 2% at Week 12 had fever. Notably, CAN therapy resulted in marked improvement in patient reported outcomes: parent/patient assessment of pain (0-100 mm, VAS) decreased from a mean of 67 mm at BL to 22 mm at Week 2 and 11 mm at Week 12. The median CHAQ disability score decreased from 1.8 at BL to 0.6 at Week 2 and 0.3 at Week 12. Between BL and Week 12, the median physicians' global assessment of SJIA activity (0-100 mm, VAS) decreased from 70 mm to 3 mm and the parents'/patients' assessment of overall well-being improved from 63 mm to 4.5 mm.
Based on this post-hoc analysis, response of the SJIA patients studied for the phase III program of CAN showed a rapid and clinically important improvement of their disease by Week 12 of therapy, with an aacr 50 or higher responses reached by the majority of the CAN-naïve pts within 2 weeks after the initial CAN dose.
Disclosure of interest
P. Quartier Grant/Research Support from: Abbvie, Chugai-Roche, Novartis, Pfizer, Consultant for: Abbott/Abbvie, BMS, Chugai-Roche, Novartis, Pfizer, Servier, SOBI, Speakers Bureau: Chugai-Roche, Novartis, Pfizer, H. Brunner Consultant for: Novartis, Genentech, Medimmune, EMD, Serono, AMS, Pfizer, UCB, Jannsen, Speakers Bureau: Genentech, T. Constantin: None declared., S. Padeh: None declared., I. Calvo: None declared., M. Erguven: None declared., L. Goffin: None declared., M. Hofer Grant/Research Support from: Novartis, T. Kallinich Grant/Research Support from: Novartis, Speakers Bureau: Roche, Novartis, ALK, S. Oliveira Grant/Research Support from: Novartis, Y. Uziel Consultant for: Novartis, S. Viola Consultant for: To Gaslini Hospital: Abbott, Astrazeneca, BMS, Centocor Research & Development, Eli Lilly and Company, "Francesco Angelini", Glaxo Smith & Kline, Italfarmaco, Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences gmbh, Xoma, Wyeth Pharmaceuticals Inc., K. Nistala: None declared., C. Wouters Grant/Research Support from: Novartis Belgium, Roche Belgium, GSK immunoinflammation USA, K. Lheritier Employee of: Novartis, J. Hruska Employee of: Novartis, K. Abrams Shareholder of: Novartis, Employee of: Novartis, A. Martini Consultant for: To Gaslini Hospital: Abbott, Astrazeneca, BMS, Centocor Research & Development, Eli Lilly and Company, "Francesco Angelini", Glaxo Smith & Kline, Italfarmaco, Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences gmbh, Xoma, Wyeth Pharmaceuticals Inc., Speakers Bureau: Bristol-Myers Squibb, Novartis, Astrazeneca, Glaxo Smith and Kline, N. Ruperto Grant/Research Support from: To Gaslini Hospital: Abbott, Astrazeneca, BMS, Centocor Research & Development, Eli Lilly and Company, "Francesco Angelini", Glaxo Smith & Kline, Italfarmaco, Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences gmbh, Xoma, Wyeth Pharmaceuticals Inc., Speakers Bureau: Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Roche, Wyeth/Pfizer, D. Lovell Grant/Research Support from: NIH, Consultant for: Astra-Zeneca, Centocor, Jansen, Wyeth, Amgen, Bristol-Meyers Squibb, Abbott, Pfizer, Regeneron, Hoffman La-Roche, Novartis, Genentech, Speakers Bureau: Genentech, Roche.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Quartier, P., Brunner, H., Constantin, T. et al. PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis. Pediatr Rheumatol 11 (Suppl 2), P169 (2013). https://doi.org/10.1186/1546-0096-11-S2-P169
- Pool Analysis
- Active Joint
- Rapid Improvement
- Important Improvement
- Disability Score